Abstract (J Korean Assoc Oral Maxillofac Surg 2019;45:68-75) Chronic recurrent multifocal osteomyelitis (CRMO) is one of the most severe form of chronic non-bacterial osteomyelitis (CNO), which could result in bone and related tissue damage. This autoinflammatory bone disorder (ABD) is very difficult for its clinical diagnosis because of no diagnostic criteria or biomarkers. CRMO in the jaw must be suspected in the differential diagnosis of chronic and recurrent bone pain in the jaw, and a bone biopsy should be considered in chronic and relapsing bone pain with swelling that is unresponsive to treatment. The early diagnosis of CRMO in the jaw will prevent unnecessary and prolonged antibiotic usage or unnecessary surgical intervention. The updated researches for the identification of genetic and molecular alterations in CNO/CRMO should be studied more for its correct pathophysiological causes and proper treatment guidelines. Although our trial consisted of reporting items from Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), there are very few articles of randomized controlled trials. This article was summarized based on the author's diverse clinical experiences. This paper reviews the clinical presentation of CNO/CRMO with its own pathogenesis, epidemiology, recent research studies, and general medications. Treatment and monitoring of the jaw are essential for the clear diagnosis and management of CNO/CRMO patients in the field of dentistry and maxillofacial surgery.
I. Introduction
Autoinflammatory disorders are known as the hyperactivation of the innate immune system without high-titter autoantibodies and autoreactive lymphocytes. Majeed syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), and pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome, were the representative autoinflammatory diseases with non-infectious osteomyelitis. Chronic non-bacterial osteomyelitis (CNO) is a kind of an autoinflammatory bone disorder (ABD) and a rare non-infectious inflammatory bone disease of unknown etiology that mostly affects children and adolescents 1, 2 . Chronic recurrent multifocal osteomyelitis (CRMO) is another diagnostic name for CNO because of its auto-inflammatory, non-infectious disorder of the bone with recurrent episodes of pain and fever resembling bacterial osteomyelitis with sterile lesion cultures that are unresponsive to antibiotic or anti-inflammatory medications. CNO/CRMO was first reported in 1972 by Giedion et al. 3 as subacute and chronic 'symmetrical' osteomyelitis. CRMO mainly occurred in the children with a female predominance, with the average age of 10 years between the ages of 4 to 14 years. The affected sites are the metaphysis of long bones, pelvis, clavicle, and mandible [1] [2] [3] [4] [5] . CNO can appear at any site in the skeleton exhibiting radiographic similarities to bacterial osteomyelitis with osteolytic and sclerotic lesions. Due to the sterile inflammation of the involved bone and atypical clinical features, the culture of the affected sites shows no bacterial infections. Only a biopsy should be considered for the final diagnosis of CNO to exclude both infected osteomyelitis and malignant bone disease.
( Table 1) This review article will reveal the basic nature of CNO/CRMO with a specific focus on the jaw for a better understanding and ideal management of ABD by maxillofacial surgeons.
II. Clinical Presentation of CNO/CRMO in the Jaw
The clinical presentation of CNO/CRMO in the jaw is very diverse with the main symptom of recurrent jaw pain and swelling with or without a general fever. Localized skin redness caused by paraosseous inflammation is a rare symptom. Inflammatory laboratory markers including erythrocyte sedimentation rate (ESR), absolute neutrophil count and white blood cell count (WBC), could be increased. These first findings in an outclinic setting could allow clinicians to suspect any kind of bacterial osteomyelitis in the jaw. CRMO in the jaw commonly has symmetrical and multifocal bony lesions in the long bones exhibiting a lytic lesion or progression to sclerosis or hyperostosis radiographically 6, 7 . Unlike other inflammatory osteomyelitis, CRMO has no infectious sources such as retained roots, periodontitis, or pathology in the oral cavity. No previous bisphosphonate therapy or radiation therapy could exclude bisphosphonate related osteonecrosis of jaw (BRONJ) or osteoradionecrosis. A bone biopsy is required to confirm the final diagnosis and to exclude any infected bacterial osteomyelitis or other malignancies. Even though the histopathological features are non-specific for CRMO, most of the bone biopsy could show slight inflammation with lymphocyte infiltration with fibrosis and lack of organisms. In adult CRMO cases, most of the patients could be usually diagnosed with complex symptoms of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO), which is currently common with additional symptoms in the Western region. Autoinflammatory organ involvement in CRMO is seen in 8% of cases with psoriasis and palmoplantar pustulosis, 10% with inflammatory bowel disease (IBD), 10% with severe acne, and 25% with ankylosing spondylitis 8, 9 . (Fig. 1) 
Epidemiology and diagnosis
Epidemiological data in CNO/CRMO is scarce and even more rare with jaw involvement data compared to other bony involvements from simple case reports, case series, and regional cohort studies. Although there have been no global epidemiologic studies until now, the greatest incidence of sporadic CNO has been found in European countries. Genetic predispositions could be suggested in the pathophysiology of sporadic CNO from familial clusters of CNO/CRMO and high incidences of comorbid-affiliated inflammatory conditions including psoriasis and IBD in CNO patients and firstdegree family members by approximately 50% 10, 11 . CNO is occurred in all ages with 7 to 12 years peak onset, female predominant. The clinical presentation of CNO is not typical having a relative self-limiting monofocal bone lesions or the most severe form of CRMO. Clinical signs of CNO/ CRMO include bone pains having arthritis, local swelling with heat and redness. And associated skin manifestations could involve palmoplantar pustulosis, psoriasis, and acne. Elevated temperatures or pathological fractures of affected vertebra could be occurred in severe cases 10, 12 . Asymptomatic bone lesions occur on the metaphysis of long bones, clavicle, humerus, vertebral column, pelvic region, femur, tibia, ankle, and calcaneus. Due to these clinical signs, CNO/CRMO could sometimes be mistaken as infectious osteomyelitis secondary to a rather mild type. Routine laboratory findings with inflammatory parameters such as WBC, C-reactive protein (CRP), and ESR, are usually normal or mildly elevated.
Radiographic imaging is essential for CNO/CRMO diagnosis with excluding differential diagnoses. Inflammatory bony lesions as radiolucent or sclerotic lesions in plain radiographs could be identified, and computed tomography or magnetic resonance imaging (MRI) are helpful tools particularly in early stage of CNO/CRMO 13, 14 , and especially in CRMO in jaw. (Fig. 2 ) MRIs could detect initial bony inflammation with surrounding soft tissue edema in the T2-weighted sequences and gadolinium-enhanced T1 sequences with fat saturation. Whole body MRI imaging could be done for checking any silent lesions, especially in the vertebral column, and for monitoring of disease occurrences such as linear fractures or surrounding soft tissue damage during the follow-up period 15, 16 . Bone biopsies for the definite and differential diagnosis of CNO/CRMO should be performed, and any suspicious disease under 2 years of age should be followed by a prompt bony biopsy, due to its rarity 17, 18 . Bony malignancies including lymphoma, leukemia, and primary and secondary bone tumors, could be diagnosed with other infectious diseases and immune diseases such as immunodeficiency in interleukin (IL)-12, Langerhans cell histiocytosis (LCH), and other autoinflammatory disorders and should be diagnosed differentially 17, 18 . Cellular atypism from innate immune cells to leukocytes and plasma cells could suggest a disease course between innate and adaptive immune mechanisms 19, 20 .
Sporadic CNO/CRMO
Sporadic CNO/CRMO has been known to have a broad clinical symptoms from mild monofocal bone inflammation to severe recurrent multifocal inflammation, such as vertebral compression fracture, arthritis, skin, or intestinal inflammatory disorder. This sporadic CNO/CRMO could be presented as clinically related phenotypes regardless of envirionmental factors. Most of sporadic type occurred in childhood or preadolescent ages between 7 to 12 years of age, additional bony inflammation could also be occurred later, but this is not severe compared with monogenic CNO/CRMO 2, 21 . The pathophysiological understanding of sporadic CNO/ CRMO is less known as the imbalance between proinflammtory and antiinflammatory cytokines, of which the mechanisms are known to govern the cell and receptor-specific induction of cytokines and chemokines 22, 23 . Monocytes from CRMO patients fail to express the immune regulatory IL-10 in response to Toll-like receptor (TLR) 4 stimulation with lipopolysaccharide. Impaired IL-10 expression is partially caused by the reduced activation of mitogen-activated protein kinases (MAPK) and extracellular signal regulated kinase (ERK) 1, resulting in impaired activation and nuclear shuttling of the transcription factor signaling protein (SP) 1 and subsequent altered recruitment of Sp-1 to the IL-10 promoter 24, 25 . A B C 
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Familial or monogenic CNO/CRMO
Familial or monogenic CNO/CRMO is not known its molecular pathophysiology, but single gene mutations involving CNO/CRMO are known to three main diseases such as Majeed syndrome by LPIN2 mutations, DIRA by IL1RN mutations, and PAPA by proline-serine-threonine phosphataseinteracting protein 1 (PSTPIP1) mutations. These monogenic disorders are associated with multiprotein complexes, inflammasomes which mediate the cleavage and subsequent release of proinflammatory cytokines IL-1β and IL-18 17, 22, [26] [27] [28] [29] . Majeed syndrome is an autosomal recessive disorder that is characterized with early-onset CRMO, Sweet syndrome-like skin rash, dyserythropoietic anemia, and joint contractures. It is caused by the loss of function mutations in the LPIN2 gene which encodes phosphatase lpin2, a phosphatidate phosphatase that plays a role in lipid metabolism, thus resulting in the overactivation of TLR4 pathways and systemic inflammation. Lipin2-deficient monocytes produce high amounts of pro-inflammatory cytokines IL-6 and tumor necrosis factor alpha (TNF-α) when stimulated by saturated fatty acids. The overexpression of LPIN2 on the other hand reduces inflammatory cytokine levels 22 . For Majeed syndrome, there is evidence that it is an IL-1β-mediated disease, since bone inflammation and serum inflammation markers improve in response to an IL-1β blockade, while TNF-α blockers have almost no effect 26 . Therefore, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and IL-1-blocking agents should be considered as empirical treatment.
DIRA is an autosomal recessive mutation in the IL1RN gene, encoding for the IL-1 receptor antagonist (IL-1RA), a post-translational regulator of IL-1 signaling resulting in uncontrolled proinflammatory cytokine and chemokine expression. DIRA is characterized by early-onset oral mucosal ulceration, pustular rash, rib widening with periostitis, multifocal osteolytic lesions, and heterotopic ossification. DIRA leads to a severe systemic inflammatory response syndrome and respiratory failure 17 due to the lack of functional IL-1RAs
and subsequently uncontrolled IL-1β signaling. Recombinant IL-1RAs therapy is known for therapeutic option 17, 27 . PAPA is an autosomal dominant mutation in the PSTPIP1 gene which binds to pyrin and regulates the actin cytoskeleton. Pyrin is a central negative regulator of the NLRP3 inflammasome by releasing of IL-1β. PAPA is characterized by pyoderma gangrenosum-like ulcerative lesions, cystic acne and sterile erosive arthritis. Therapeutic options involve local and/or systemic steroids, thalidomide, cyclosporine, tacrolimus, intravenous immunoglobulin, TNF-α blockers, and IL-1 blocking agents 28, 29 .
III. CNO/CRMO Studies
CNO in the jaw presents with mild or non-specific clinical symptoms, which is not recognized by patients and medical staff resulting in a delayed final diagnosis. Although CNO is associated with other general syndromes or genetic diseases including SAPHO, Majeed syndrome, DIRA, and PAPA, a genetic or molecular basis for animal studies have been provoked and found to be associated with other autoinflammatory conditions such as IBD, acne, ankylosing spondylitis, and psoriasis.
Microbiome in CNO/CRMO
A microbiota, microbiome, is the collective genomes of commensal or pathogenic microorganisms in plants or animals. Disturbances to the microbiome, particularly of the gut, have been proven to contribute to altered immune cell distribution and inflammatory phenotypes in several diseases including immunologic, hormonal, and metabolic disorders 30 . In rheumatoid arthritis, the replacement of Lactobacillus spp. with Prevotella spp. has been linked to disease activity and outcomes. Liao et al. 31 published the first study that found that disturbances in the gut microbiome may contribute to sterile bone inflammation. In humans, it could be proposed a potential pathophysiological connection of an altered skin microbiome and aseptic bone inflammation in CNO, because both of severe cystic acne and CNO, share the imbalanced expression and secretion of proinflammatory antiinflammatory cytokines [32] [33] [34] .
Murine models of CRMO
Two well-characterized murine models have been developed, chronic multifocal osteomyelitis (cmo) mice carrying a spontaneous homozygous mutation (p.L98P) and lupo mice carrying a chemically-induced homozygous mutation (p.I282N) in the Pstpip2 gene 35, 36 . Two models could be developed to cytokine and chemokine dysregulation, systemic inflammation, extramedullary hematopoiesis, skin inflammation, and sterile osteomyelitis. As in the case of CRMO patients, cmo mice exhibit a central involvement of IL-1β in disease pathophysiology and the complete deficiency of Pstpip2 gene results in the dysregulated production of IL-1β by neutrophils and enhanced osteoclastogenesis 35 .
Chemokine and cytokine dysregulation in CNO/ CRMO
The molecular mechanisms of CNO/CRMO have been suggested as many different pathways and hypotheses, inflammasome and consequent imbalance between proinflammatory and anti-inflammatory cytokines.
TLR4/MAPK/inflammasome signaling pathway could contribute to the inflammatory phenotype in CRMO, inflammatory bone loss and synovial inflammation in IL-10-deficient mice were linked to increased NOD-like receptor protein 3 (NLRP3) inflammasome activation 37, 38 . This activation will increase mRNA expression of inflammasome including ASC, NLRP3, and caspase-1, as well as increased IL-1β transcription and release from monocytes of CRMO patients 37, 38 . An immunomodulatory reversible function by IL-10 and IL-19 on enhanced inflammasome activation with IL-1β secretion could be suggested 23 . The imbalanced expression of antiinflammtory cytokines such as IL-10 and IL-19, and pro-inflammatory cytokines such as IL-1, IL-6, TNF-α, and IL-20, may result in increased osteoclast differentiation and activation through enhanced interactions between the receptor activator of nuclear factor-κB (RANK) and its soluble ligand RANKL on osteoclast precursor cells 19, 33 . IL-10 expression is predetermined by genetic variants within the IL-10 proximal promoter region, by blocking encoding for high IL-10 expression (GCC) 27 , which is one of clue for the IL-10 medication to the CRMO patients.
Additionally, a CRMO susceptibility gene has been identified through whole exome sequencing and gene expression microarrays. FBLIM1 has been suggested to act as an antiinflammatory molecule that controls bone remodeling through the regulation of RANKL activation through ERK1/2 phosphorylation. On the transcriptional level, FBLIM1 expression is regulated by the transcription factor STAT3. Since the immune regulatory cytokine IL-10 induces STAT3 activation, the aforementioned haplotype blocks within the IL-10 promoter may be involved in the pathophysiology of CNO. Cox et al. 39 demonstrated that IL-10 promoter haplotypes may contribute to reduced STAT3 activation. Although preliminary results regarding the kinetics of innate and adaptive inflammatory responses in CNO/CRMO, outline for future targeted medications should be continued based on the specific expressions of cytokines and chemokines 19, 40 .
IV. Treatment and Biomarkers for CNO/CRMO in the Jaw
The treatment of patients with CNO/CRMO in the jaw should not always be through surgical means and that medications should be considered. Only small portions of bone biopsies including both cortical and marrow bony architecture could be confirmed for the exclusion of any bacterial osteomyelitis. NSAIDs are representative medication drugs for CNO/CRMO. Other recently approved medications include corticosteroids, bisphosphonates and disease-modifying antirheumatic drugs (DMARDs) including methotrexate, sulfasalazine and anti-TNF agents. (Fig. 3) 
Biomarkers for CNO diagnosis and monitoring
Sstandardized and accepted parameters have not yet to be reported despite many basic studies and follow-up clinical studies regarding CNO/CRMO biomarkers. Known classical inflammation markers, such as CRP and ESR, are not specific. Therefore, in unclear cases, bone biopsies must be considered as the first action prior to prescribing any medications 32 . A clinical score for CNO patients was developed by Jansson et al. 41 , and Beck et al. 42 presented the Pediatric CNO (PedCNO) score, which includes 5 measurements such as ESR, number of radiological lesions, severity of disease estimated by the physician, severity of disease estimated by the patient or parent, and the Childhood Health Assessment Questionnaire. However, the clinical score has not been considered for other ABD involving the jaw, metabolic disorders, lymphoma, leukemia, LCH, and mycobacterial bone infections. El-Shanti and Ferguson 11 identified a set of nine serum inflammation markers including IL-6, IL-12, MIG, RANTES, IL-1RA, soluble IL-2 receptor (sIL-2R), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein1b (MIP-1b) and mast cell derived chemokine eotaxin. These serum protein arrays may be used for the diagnosis of CNO/ CRMO, but larger multi-institute cohort studies should be performed. Unbalanced cytokine and chemokine expression could be used for the diagnosis of CNO/CRMO 19, 38, 43 . Molecular works of monocytes from CRMO patients showed decreased levels of IL-10, IL-1RA and granulocyte monocyte colonystimulating factor, and showed increased levels of IL-1β, IL-6, TNF-α, IL-8, Interferon gamma-induced protein 10, MCP-1, MIG, MIP-1a, and MIP-1b 38, 43 . And the increased levels of the NLRP3 from inflammatory infiltrates of CNO/CRMO could be translated into IL-1β and IL-10 protein expression in bacterial osteomyelitis. This NLRP3 component in the gene expression profiles would be applicated in the CNO/CRMO in jaw cases. Not like in the bacterial osteomyelitis, predominant neutrophils and monocytes are usually moderately infiltrated with bone marrow fibrosis in the CNO/CRMO bone biopsy 32, 33 .
Treatments of CNO in the jaw
Any pathological involvement of the jaw should be managed with medicinal approaches at first and not with surgical considerations. Usually, NSAIDs, corticosteroids, and DMARDs such as methotrexate or sulfasalazine, could be considered for general CNO/CRMO management. Anti-TNF agents including proinflammatory cytokines and bisphosphonates (BPs) could be additionally considered. (Fig. 3) NSAIDs are the first-line treatment of choice for the treatment of initial CNO/CRMO in jaw patients with the most common choice being 10 to 15 mg/kg/day of naproxen in 2 divided doses which is effective in 70% of patients 9 . NSAIDs are effective in approximately two-thirds of CNO/CRMO patients, and NSAIDs are more effective in CNO patients compared with only CRMO patients 24 . And another data showed that NSAIDs did not induce true real remission in CNO patients with a clinically asymptomatic state in 43% after 6 months and in 51% at 12 months, and also NSAIDs may not be sufficient for long-term remission in the majority of patients 9, 42 . For the management of CRMO in jaw patients, definitely NSAIDs should be considered as the first medication only excluding the relapsed or no completed remission cases. Cyclooxygenases inhibition is activated by NSAIDs for the conversion of arachidonic acid into prostaglandins, which is essential procedure of osteoclast activation in jaw 3 . Jaw edema or any kinds of structural damage with NSAIDs should be followed-up periodically.
Widely accepted treatment consensus remains empirical, despite many collected case series of NSAID medications, measurements of disease activity, treatment goal definitions, and outcome measurements. Corticosteroids in CNO/CRMO management could be recommended as an intermediately between failed NSAIDs and other drugs initiation. Oral glucocorticoid medication is recommended as 2 mg prednisone/ kg/day for 1 week and tapered discontinuation by 25% every 5 days 44 . Intravenous steroid infusion could be effective in selected recurrent patients but a standardized medication protocol is not known yet 45 . The inhibition pathway of phospholipase A2 is well known for reduced prostaglandin levels as the corticosteroids mechanisms. In the case of CNO/CRMO patients, the inhibition of nuclear factor-κB-dependent gene activation could be also useful for the reduced proinflammatory cytokine levels such as IL-6 and the TNF-α gene 39 . In spite of its quick control of inflammatory activity, longterm effects had not been expected in CNO/CRMO patients. The effective management with bisphosphonate or anti-TNF agents have been reported to be highly effective for the longlasting remission 12, 33, 42 . The representative osteoclast inhibition drug, BPs, could increase bone mass with improved mineralization in the postmenopausal and glucocorticoidinduced osteoporosis. Although BPs have severe side effects such as BRONJ, this is effective in CNO/CRMO patients by modify pains through suppression of proinflammatory cytokines, such as TNF-α, IL-6, and IL-1 46 . BPs could be recommended in no effective cases of NSAIDs, corticosteroids, or DMARDs. Among BPs, pamidronate could be first recommended in the refractory pediatric CNO/CRMO patients, which could be administered as an initial dose of 0.5 mg/kg/ day followed by 1 mg on days 2 and 3 mg every 3 months, or 1 dose of 1 mg/kg every month for 1 to 6 months 32, [47] [48] [49] . Due to its exact pathogenesis is not revealed, any molecules during having its role in a little bit known sequences could be blocked for the additional treatment option in CNO/ CRMO patients. Methotrexate and sulfasalazine are known to reduce inflammatory cytokine expression in recalcitrant CNO/CRMO patients and are more commonly used in North America and Europe 1 . More recently, DMARDs may be used more and more due to several side effects or no complete remission of NSAIDs especially in CRMO in jaw 24 . Since IL-1 and TNF-α are generally important in the inflammatory pathogenesis, IL-1 blocking agents and TNF-α inhibitors can be also considered in CNO/CRMO treatment. TNF inhibitors could also be used with NSAIDs and corticosteroids for specifically blocking TNF-α and for restoring the balance between this highly potent proinflammatory cytokine and immune modulatory cytokines IL-10 and IL-19 [23] [24] [25] 27 .
Although there is no reliable report, RANKL blockade with denosumab, which is the recombinant RANK ligand inhibitor, may reduce osteoclast activation and inflammatory bone loss in CRMO in jaw. These functions are deduced from the differentiation and activation of osteoclasts, TNF-α versus IL-10 and IL-19, which are counteracting mediators 50 . Recently, biomarkers including IL-12, MCP-1, and sIL-2R were introduced for acting of treatment response to NSAIDs 51, 52 . Further evaluation of these medications, such as IL-12, MCP-1, and sIL-2R, could be used as the progression of CNO/CRMO in jaw.
V. Conclusion
CRMO in jaw must be diagnosed with the differentiation of chronic bacterial osteomyelitis, and a bone biopsy is essential. The early diagnosis of CRMO in jaw will prevent unnecessary and prolonged antibiotic usage and unnecessary surgical intervention. The updated researches of several pathophysiological alterations in CNO/CRMO should be studied more for its exact causes and allow for the creation of target-directed treatment options.
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